kneat.com (TSE:KSI) Upgraded by Cibc World Mkts to “Strong-Buy” Rating

Cibc World Mkts upgraded shares of kneat.com (TSE:KSI) to a strong-buy rating in a research report released on Tuesday, Zacks.com reports.

Several other analysts have also weighed in on KSI. CIBC set a C$6.00 price target on kneat.com and gave the company an “outperform” rating in a report on Tuesday. Ventum Cap Mkts raised shares of kneat.com to a “strong-buy” rating in a research note on Wednesday, August 7th.

kneat.com Stock Performance

kneat.com stock opened at C$4.75 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 1.47 and a debt-to-equity ratio of 95.14. kneat.com has a twelve month low of C$2.73 and a twelve month high of C$5.17. The company’s 50-day moving average price is C$4.76 and its 200-day moving average price is C$4.44. The company has a market cap of C$408.50 million, a PE ratio of -29.69, a price-to-earnings-growth ratio of 597.67 and a beta of 1.08.

kneat.com (TSE:KSI) last issued its quarterly earnings data on Tuesday, August 6th. The company reported C($0.04) earnings per share for the quarter, hitting the consensus estimate of C($0.04). The company had revenue of C$11.68 million for the quarter, compared to analysts’ expectations of C$11.45 million. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. On average, equities research analysts forecast that kneat.com will post -0.12 EPS for the current fiscal year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.